Design, analysis and presentation of factorial randomised controlled trials

被引:214
作者
Alan A Montgomery
Tim J Peters
Paul Little
机构
[1] Division of Primary Health Care, University of Bristol, Cotham House, Bristol BS6 6JL, Cotham Hill
[2] Community Clinical Sciences Division, Southampton University, Aldermoor Health Centre
关键词
Factorial Design; Binary Outcome; Adequate Power; Multivariable Regression Model; Factorial Trial;
D O I
10.1186/1471-2288-3-26
中图分类号
学科分类号
摘要
Background: The evaluation of more than one intervention in the same randomised controlled trial can be achieved using a parallel group design. However this requires increased sample size and can be inefficient, especially if there is also interest in considering combinations of the interventions. An alternative may be a factorial trial, where for two interventions participants are allocated to receive neither intervention, one or the other, or both. Factorial trials require special considerations, however, particularly at the design and analysis stages. Discussion: Using a 2 × 2 factorial trial as an example, we present a number of issues that should be considered when planning a factorial trial. The main design issue is that of sample size. Factorial trials are most often powered to detect the main effects of interventions, since adequate power to detect plausible interactions requires greatly increased sample sizes. The main analytical issues relate to the investigation of main effects and the interaction between the interventions in appropriate regression models. Presentation of results should reflect the analytical strategy with an emphasis on the principal research questions. We also give an example of how baseline and follow-up data should be presented. Lastly, we discuss the implications of the design, analytical and presentational issues covered. Summary: Difficulties in interpreting the results of factorial trials if an influential interaction is observed is the cost of the potential for efficient, simultaneous consideration of two or more interventions. Factorial trials can in principle be designed to have adequate power to detect realistic interactions, and in any case they are the only design that allows such effects to be investigated.
引用
收藏
页码:1 / 5
页数:4
相关论文
共 14 条
[1]  
Grimes D.A., Schulz K.F., An overview of clinical research: The lay of the land, Lancet, 359, pp. 57-61, (2002)
[2]  
Watson M., Gunnell D., Peters T., Brookes S., Sharp D., Guidelines and educational outreach visits from community pharmacists to improve prescribing in general practice: A randomised controlled trial, Journal of Health Services Research and Policy, 6, pp. 207-213, (2001)
[3]  
Montgomery A.A., Fahey T., Peters T.J., A factorial randomised controlled trial of decision analysis and an information video plus leaflet for newly diagnosed hypertensive patients, Br J Gen Pract, 53, pp. 446-453, (2003)
[4]  
Bankhead C., Richards S.H., Peters T.J., Sharp D.J., Hobbs F.D.R., Brown J., Et al., Improving attendance for breast screening among recent non-attenders: A randomised controlled trial of two interventions in primary care, Journal of Medical Screening, 8, pp. 99-105, (2001)
[5]  
Peveler R., George C., Kinmonth A.-L., Campbell M., Thompson C., Effect of antidepressant drug counselling and information leaflets on adherence to drug treatment in primary care: Randomised controlled trial, BMJ, 319, pp. 612-615, (1999)
[6]  
Sheikh A., Smeeth L., Ashcroft R., Randomised controlled trials in primary care: Scope and application, Br J Gen Pract, 52, pp. 746-751, (2002)
[7]  
Ottenbacher K.J., Interpretation of interaction in factorial analysis of variance design, Statistics in Medicine, 10, pp. 1565-1571, (1991)
[8]  
Brookes S.T., Whitley E., Peters T.J., Mulheran P.A., Egger M., Davey Smith G., Subgroup analyses in randomised controlled trials quantifying the risks of false-positives and false-negatives, Health Technol Assess, 5, 33, (2001)
[9]  
Moher D., Schulz K.F., Altman D.G., The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials, Lancet, 357, pp. 1191-1194, (2001)
[10]  
Senn S., Statistical Issues in Drug Development, (1997)